Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.

about

Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.

Item

http://www.wikidata.org/entity/Q39600375

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Factor VIII associated with li ...... tibodies in hemophilia A mice.

@en

Factor VIII associated with li ...... tibodies in hemophilia A mice.

@nl

type

Item

label

Factor VIII associated with li ...... tibodies in hemophilia A mice.

@en

Factor VIII associated with li ...... tibodies in hemophilia A mice.

@nl

prefLabel

Factor VIII associated with li ...... tibodies in hemophilia A mice.

@en

Factor VIII associated with li ...... tibodies in hemophilia A mice.

@nl

P1476

Factor VIII associated with li ...... ntibodies in hemophilia A mice

@en

P2093

Donald E Mager

http://www.w3.org/2001/XMLSchema#string

Krithika A Shetty

http://www.w3.org/2001/XMLSchema#string

Sathy V Balu-Iyer

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor

The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion.

Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice

Inhibition of human factor VIIIa by anti-A2 subunit antibodies.

Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.

Clustered basic residues within segment 484-510 of the factor VIIIa A2 subunit contribute to the catalytic efficiency for factor Xa generation.

Factor VIII inhibitors.

Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid.

Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice.

Current difficulties and recent advances in bypass therapy for the management of hemophilia with inhibitors: a new and practical formulation of recombinant factor VIIa.

P304

409-420

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/BDD.2023

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Matthew P Kosloski

P577

2016-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27418232

http://www.w3.org/2001/XMLSchema#string

P921

hemophilia

hemophilia A

Coagulation factor VIII

nanoparticle

P932

5125252

http://www.w3.org/2001/XMLSchema#string